496 related articles for article (PubMed ID: 27438521)
21. The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa.
Khairallah M; Zaouali S; Messaoud R; Chaabane S; Attia S; Ben Yahia S; Hmidi K
Int Ophthalmol; 2007; 27(2-3):125-30. PubMed ID: 17203358
[TBL] [Abstract][Full Text] [Related]
22. Analysis of 87 cases with Vogt-Koyanagi-Harada disease.
Mondkar SV; Biswas J; Ganesh SK
Jpn J Ophthalmol; 2000; 44(3):296-301. PubMed ID: 10913650
[TBL] [Abstract][Full Text] [Related]
23. Bilateral acute angle closure glaucoma as a presentation of vogt-koyanagi-harada syndrome in four chinese patients: a small case series.
Yao J; Chen Y; Shao T; Ling Z; Wang W; Qian S
Ocul Immunol Inflamm; 2013 Aug; 21(4):286-91. PubMed ID: 23718571
[TBL] [Abstract][Full Text] [Related]
24. Vogt-Koyanagi-Harada disease in Thailand.
Yodmuang T; Rothova A; Kunavisarut P; Pathanapitoon K
Ocul Immunol Inflamm; 2012 Dec; 20(6):419-22. PubMed ID: 23163754
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
26. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
27. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
28. Occurrence of and Risk Factors for Ocular Hypertension and Secondary Glaucoma in Juvenile Idiopathic Arthritis-associated Uveitis.
Stroh IG; Moradi A; Burkholder BM; Hornbeak DM; Leung TG; Thorne JE
Ocul Immunol Inflamm; 2017 Aug; 25(4):503-512. PubMed ID: 27003850
[TBL] [Abstract][Full Text] [Related]
29. Reversal of Peripheral Iris Depigmentation Associated with Vogt-Koyanagi-Harada Disease.
Tobaigy MF; AlBloushi AF; Al-Dhibi HA
Ocul Immunol Inflamm; 2024 May; 32(4):424-428. PubMed ID: 36657743
[TBL] [Abstract][Full Text] [Related]
30. Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.
Arevalo JF; Lasave AF; Gupta V; Kozak I; Al Harbi MB; Al Rushood AA; Al Dhibi HA
Ocul Immunol Inflamm; 2016 Oct; 24(5):521-9. PubMed ID: 26399962
[TBL] [Abstract][Full Text] [Related]
31. Vogt Koyanagi Harada disease: treatment and visual prognosis.
Alam M; Iqbal M; Khan BS; Hussain I
J Coll Physicians Surg Pak; 2013 Oct; 23(10):740-2. PubMed ID: 24112262
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in Vogt-Koyanagi-Harada disease.
Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D; Abu El-Asrar AM
Int Ophthalmol; 2007; 27(2-3):201-10. PubMed ID: 17435968
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy.
Takayama K; Obata H; Takeuchi M
Ocul Immunol Inflamm; 2020 Apr; 28(3):509-512. PubMed ID: 31268769
[No Abstract] [Full Text] [Related]
34. Vogt-Koyanagi-Harada disease in children.
Abu El-Asrar AM; Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D
Eye (Lond); 2008 Sep; 22(9):1124-31. PubMed ID: 17479116
[TBL] [Abstract][Full Text] [Related]
35. Vogt-Koyanagi-Harada disease associated with anterior ischemic optic neuropathy in a young woman presenting as acute angle closure glaucoma.
Patyal S; Narula R; Thulasidas M
Indian J Ophthalmol; 2020 Sep; 68(9):1937-1938. PubMed ID: 32823420
[No Abstract] [Full Text] [Related]
36. Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.
Couto C; Schlaen A; Frick M; Khoury M; Lopez M; Hurtado E; Goldstein D
Ocul Immunol Inflamm; 2018; 26(3):485-489. PubMed ID: 27775450
[TBL] [Abstract][Full Text] [Related]
37. Incidence and management of glaucoma in Vogt-Koyanagi-Harada syndrome.
Forster DJ; Rao NA; Hill RA; Nguyen QH; Baerveldt G
Ophthalmology; 1993 May; 100(5):613-8. PubMed ID: 8098519
[TBL] [Abstract][Full Text] [Related]
38. Vogt-Koyanagi-Harada disease: clinical outcomes.
Bykhovskaya I; Thorne JE; Kempen JH; Dunn JP; Jabs DA
Am J Ophthalmol; 2005 Oct; 140(4):674-8. PubMed ID: 16226518
[TBL] [Abstract][Full Text] [Related]
39. Vogt-Koyanagi-Harada Syndrome in a Group of Patients in Two Ophthalmology Referral Centers in Bogotá, Colombia.
Guayacán CL; Galindo-Mendez B; de-la-Torre A
Ocul Immunol Inflamm; 2018; 26(7):1123-1127. PubMed ID: 28910557
[TBL] [Abstract][Full Text] [Related]
40. Peripheral iris depigmentation and ocular hypotony: result of the natural course of non-treated Vogt-Koyanagi-Harada (VKH) disease.
Attia S; Zaouali S; Bettaieb A; Yahia SB; Khairallah M
Int Ophthalmol; 2007; 27(2-3):221-2. PubMed ID: 17318319
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
